Evidence map›Paper›PMID 31073193›Full record

ArticleScientific reports2019

A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology.

Olivia Candini, Giulia Grisendi, Elisabetta Manuela Foppiani, Matteo Brogli, Beatrice Aramini, Valentina Masciale, Carlotta Spano, Tiziana Petrachi, Elena Veronesi, Pierfranco Conte and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 188 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Hybrid biofabricated blood vessel for medical devices testing.Science and technology of advanced materials · 2024
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Three-dimensional models: a novel approach for lymphoma research.Journal of cancer research and clinical oncology · 2022
    Review
  17. Article
  18. GD2 CAR T cells against human glioblastoma.NPJ precision oncology · 2021
    Article
  19. Article
  20. Mechanical Studies of the Third Dimension in Cancer: From 2D to 3D Model.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Olivia CandiniRigenerand srl, Medolla, Modena, Italy. olivia.candini@rigenerand.it.
Giulia GrisendiRigenerand srl, Medolla, Modena, Italy.
Elisabetta Manuela FoppianiRigenerand srl, Medolla, Modena, Italy.
Matteo BrogliRigenerand srl, Medolla, Modena, Italy.
Beatrice AraminiDivision of Chest Surgery, Department of Medical and Surgical Sciences for Children & Adults, University-Hospital of Modena and Reggio Emilia, Modena, Italy.
Valentina MascialeDivision of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University-Hospital of Modena and Reggio Emilia, Modena, Italy.
Carlotta SpanoRigenerand srl, Medolla, Modena, Italy.
Tiziana PetrachiTechnopole of Mirandola, Mirandola, Modena, Italy.
Elena VeronesiTechnopole of Mirandola, Mirandola, Modena, Italy.
Pierfranco ConteMedical Oncology 2, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy.
Giorgio MariRigenerand srl, Medolla, Modena, Italy.
Massimo DominiciRigenerand srl, Medolla, Modena, Italy. massimo.dominici@unimore.it.ORCID http://orcid.org/0000-0002-4007-1503
University of Modena and Reggio Emilia · ITOspedale di Mirano · ITMedigene (Germany) · DEUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumors develop within complex cell-to-cell interactions, with accessory cells playing a relevant role starting in the early phases of cancer progression. This event occurs in a three-dimensional (3D) environment, which to date, has been difficult to reproduce in vitro due to its complexity. While bi-dimensional cultures have generated substantial data, there is a progressive awareness that 3D culture strategies may rapidly increase the understanding of tumor development and be used in anti-cancer compound screening and for predicting response to new drugs utilizing personalized approaches. However, simple systems capable of rapidly rebuilding cancer tissues ex-vivo in 3D are needed and could be used for a variety of applications. Therefore, we developed a flat, handheld and versatile 3D cell culture bioreactor that can be loaded with tumor and/or normal cells in combination which can be monitored using a variety of read-outs. This biocompatible device sustained 3D growth of tumor cell lines representative of various cancers, such as pancreatic and breast adenocarcinoma, sarcoma, and glioblastoma. The cells repopulated the thin matrix which was completely separated from the outer space by two gas-permeable membranes and was monitored in real-time using both microscopy and luminometry, even after transportation. The device was tested in 3D cytotoxicity assays to investigate the anti-cancer potential of chemotherapy, biologic agents, and cell-based therapy in co-cultures. The addition of luciferase in target cancer cells is suitable for comparative studies that may also involve parallel in vivo investigations. Notably, the system was challenged using primary tumor cells harvested from lung cancer patients as an innovative predictive functional assay for cancer responsiveness to checkpoint inhibitors, such as nivolumab. This bioreactor has several novel features in the 3D-culture field of research, representing a valid tool useful for cancer investigations, drug screenings, and other toxicology approaches.

Indexed as

Antineoplastic AgentsCell Culture TechniquesCell Line, TumorCell ProliferationCoculture TechniquesDrug Evaluation, PreclinicalGenetic TherapyHumansLung NeoplasmsNeoplasmsNivolumabAntineoplastic AgentsNivolumab

Identifiers

PMID31073193
PMCPMC6509120
OpenAlexW2944434139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.